Bruce Goldsmith
Geen lopende functies
Vermogen: 27 300 $ op 29-02-2024
Profiel
Bruce A.
Goldsmith is former President, Chief Executive Officer & Director at Passage Bio, Inc., former Chief Executive Officer of Civetta Therapeutics LLC, former Chief Operating Officer at Lycera Corp., former Product Director at Johnson & Johnson, former Venture Partner at Deerfield Management Co. LP, former Senior Vice President-Corporate Development of Allos Therapeutics, Inc. and former Vice President-Strategic Marketing at GPC Biotech, Inc.
He received a doctorate from the University of Pennsylvania, an undergraduate degree from Colgate University and an MBA from Columbia Business School.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
PASSAGE BIO, INC.
0.03% | 15-03-2023 | 15 965 ( 0.03% ) | 27 300 $ | 29-02-2024 |
Eerdere bekende functies van Bruce Goldsmith
Bedrijven | Functie | Einde |
---|---|---|
PASSAGE BIO, INC. | Chief Executive Officer | 31-05-2022 |
Civetta Therapeutics LLC
Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Civetta Therapeutics LLC develops therapeutics for cancers and other diseases. The company was founded by William Sellers and Eric Fischer and is headquartered in Cambridge, MA. | Chief Executive Officer | 01-01-2020 |
Deerfield Management Co. LP
Deerfield Management Co. LP Investment ManagersFinance Deerfield Management Co. LP (Deerfield) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Peter Drake in 1994. They are wholly owned by James E. Flynn and are controlled by its general partner, Flynn Management LLC. Deerfield provides discretionary investment management services in the healthcare sector to domestic and offshore private pooled investment vehicles and their related alternative investment vehicles. | Corporate Officer/Principal | 01-01-2020 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Chief Operating Officer | 01-01-2019 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 05-09-2012 |
Opleiding van Bruce Goldsmith
University of Pennsylvania | Doctorate Degree |
Colgate University | Undergraduate Degree |
Columbia Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
JOHNSON & JOHNSON | Health Technology |
PASSAGE BIO, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Deerfield Management Co. LP
Deerfield Management Co. LP Investment ManagersFinance Deerfield Management Co. LP (Deerfield) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Peter Drake in 1994. They are wholly owned by James E. Flynn and are controlled by its general partner, Flynn Management LLC. Deerfield provides discretionary investment management services in the healthcare sector to domestic and offshore private pooled investment vehicles and their related alternative investment vehicles. | Finance |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |
GPC Biotech, Inc.
GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
Civetta Therapeutics LLC
Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Civetta Therapeutics LLC develops therapeutics for cancers and other diseases. The company was founded by William Sellers and Eric Fischer and is headquartered in Cambridge, MA. | Health Technology |